

1.3.1.1 Professional Information for medicines for human use

SCHEDULING STATUS

S4

1 NAME OF THE MEDICINE**CLAMENTIN 1000 mg (film-coated tablet)****2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

CLAMENTIN 1000 mg tablets contain amoxicillin trihydrate equivalent to amoxicillin 875 mg and potassium clavulanate equivalent to clavulanic acid 125 mg.

Sugar free.

For full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

White to pale yellow, oblong tablet, scored on both sides. Approximately 10 x 22 mm.

4 CLINICAL PARTICULARS**4.1 Therapeutic indications**

CLAMENTIN 1000 mg formulation is indicated for the treatment of infections caused by amoxicillin-resistant organisms producing beta-lactamases sensitive to clavulanic acid:

- Upper respiratory tract infections, such as sinusitis, recurrent otitis media, tonsillitis.
- Lower respiratory tract infections, such as bronchitis and bronchopneumonia.
- Genito-urinary tract infections, such as cystitis, urethritis, pyelonephritis.
- Skin and soft tissue infections.

1.3.1.1 Professional Information for medicines for human use

CLAMENTIN 1000 mg formulation will also be effective in the treatment of infections caused by amoxicillin-sensitive organisms at the appropriate amoxicillin dosage since in this situation the clavulanic acid component does not contribute to the therapeutic effect.

4.2 Posology and method of administration

Posology

For Oral Formulations:

CLAMENTIN 1000 mg should be taken immediately before a meal.

General Information:

For infections caused by amoxicillin-sensitive organisms the dosage is that approved for amoxicillin as the clavulanic acid component does not contribute to the therapeutic effect.

Adults:

- The adult dose is one CLAMENTIN 1000 mg tablet every 12 hours at the start of a meal.

Special populations

Impaired Renal Function:

- Both amoxicillin and clavulanic acid are excreted by the kidneys and the serum half-life of each increase in patients with renal failure. Therefore, the dose may need to be reduced or the interval extended.
- Dosage adjustments are based on the maximum recommended level of amoxicillin.
- CLAMENTIN 1000 mg should not be used in patients with glomerular filtration rate of less than 30 ml/minute.
- Haemodialysis decreases serum concentrations of both amoxicillin and clavulanic acid and an additional dose should be administered at the end of dialysis.

1.3.1.1 Professional Information for medicines for human use

Dosage Guide:

Amoxicillin-Sensitive Organisms

Product	Upper Respiratory Tract Infections	Lower Respiratory Tract Infections	Urinary Tract Infections	Skin & Soft Tissue Infections
CLAMENTIN 1000 mg	1 Tablet 12 hourly	1 Tablet 12 hourly	1 Tablet 12 hourly	1 Tablet 12 hourly

Amoxicillin-Resistant Organisms

Product	Upper Respiratory Tract Infections (Otitis media)	Lower Respiratory Tract Infections (Bronchitis)	Urinary Tract Infections	Skin & Soft Tissue Infections
CLAMENTIN 1000 mg	1 Tablet 12 hourly	1 Tablet 12 hourly	1 Tablet 12 hourly	1 Tablet 12 hourly

Method of administration

- For oral use.

4.3 Contraindications

- Hypersensitivity to penicillins, cephalosporins, other beta-lactam medicines (e.g carbapenem or monobactam) or to any of the excipients. Cross-sensitivity between penicillins and cephalosporins is well documented.
- CLAMENTIN 1000 mg is contraindicated in patients with a previous history of amoxicillin/clavulanic-associated jaundice/hepatic dysfunction.

4.4 Special warnings and precautions for use

Hypersensitivity reactions:

1.3.1.1 Professional Information for medicines for human use

- Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. Hypersensitivity reactions can also progress to Kounis syndrome, a serious allergic reaction that can result in myocardial infarction (*see section 4.8*). Before, initiating therapy with CLAMENTIN 1000 mg, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactam medicines or other allergens. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity, who have experienced severe reactions when treated with cephalosporins.
- If an allergic reaction occurs, CLAMENTIN 1000 mg should be discontinued and the appropriate therapy instituted. Serious anaphylactic reactions may require immediate emergency treatment with adrenaline. Oxygen, intravenous steroids and airway management, including intubation may also be required.
- CLAMENTIN 1000 mg should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.
- Drug-induced enterocolitis syndrome (DIES) has been reported mainly in children receiving amoxicillin/clavulanate (*see section 4.8*). DIES is an allergic reaction with the leading symptom of protracted vomiting (1-4 hours after intake of amoxicillin/clavulanate) in the absence of allergic skin or respiratory symptoms. Further symptoms could comprise abdominal pain, diarrhoea, hypotension or leucocytosis with neutrophilia. There have been severe cases including progression to shock.

Non-susceptible microorganisms:

1.3.1.1 Professional Information for medicines for human use

- Since CLAMENTIN 1000 mg contains amoxicillin, an aminopenicillin, it is not the treatment of choice in patients presenting with sore throat or pharyngitis, because of the possibility that the underlying cause is infectious mononucleosis, in the presence of which there is a high incidence of rash (morbilliform rash) if amoxicillin is used.
- The use of CLAMENTIN 1000 mg may lead to the selection of resistant strains of organisms and sensitivity testing should, therefore, be carried out whenever possible, to demonstrate the appropriateness of therapy.
- CLAMENTIN 1000 mg is not suitable for use when there is a high risk that the presumptive pathogens have reduced susceptibility or resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid. CLAMENTIN 1000 mg should not be used to treat penicillin-resistant *S. pneumoniae*.

Overgrowth of non-susceptible microorganisms:

- Prolonged use may result in overgrowth of non-susceptible organisms.
- *Pseudomembranous enterocolitis* has been reported.
Antibiotic-associated colitis has been reported. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of CLAMENTIN 1000 mg. Should antibiotic-associated colitis occur, CLAMENTIN 1000 mg should immediately be discontinued and a doctor should be consulted.
- Anti-peristaltic medicines are contraindicated in this situation.

Prolonged therapy:

- Periodic assessment of organ function, including renal, hepatic and haematopoietic functions, is advisable during prolonged therapy.
- The possibility of superinfections with mycotic or bacterial pathogens should be kept in mind during therapy. If superinfections occur (usually involving *Aerobacter*,

1.3.1.1 Professional Information for medicines for human use

Pseudomonas or *Candida*), CLAMENTIN 1000 mg should be discontinued and/or appropriate therapy instituted.

Anticoagulants:

- Prolongation of prothrombin time has been reported rarely in patients receiving CLAMENTIN 1000 mg. Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently (*see section 4.5*).

Impaired hepatic function:

- Changes in liver function tests have been observed in some patients receiving CLAMENTIN 1000 mg.
- CLAMENTIN 1000 mg should be used with caution in patients with evidence of hepatic dysfunction (*see section 4.3*).
- Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. The hepatic effects are usually reversible. However, in extremely rare circumstances, death has been reported. These have almost always been cases associated with serious underlying disease or concomitant medication (*see section 4.8*).
- Transient hepatitis and cholestatic jaundice have been reported.

Impaired renal function:

- In patients with moderate or severe renal impairment CLAMENTIN 1000 mg dosage should be adjusted (*see section 4.2*).
- CLAMENTIN 1000 mg should not be used in patients with a glomerular filtration rate of less than 30 ml/minute (*see section 4.2*).

Convulsions:

- Convulsions may occur in patients with impaired renal function or in those receiving high doses (*see section 4.8*).

Crystalluria:

1.3.1.1 Professional Information for medicines for human use

- In patients with reduced urine output, crystalluria (including acute renal injury) has been observed very rarely, predominantly with parenteral therapy. When high doses are administered, adequate fluid intake and urinary output must be maintained in order to reduce the possibility of amoxicillin crystalluria (see section 4.8 and 4.9).

Jarisch-Herxheimer reaction:

- Caution is needed when administering CLAMENTIN 1000 mg to patients with syphilis, as the Jarisch-Herxheimer reaction may occur in these patients.

Lymphatic leukaemia:

- CLAMENTIN 1000 mg should be given with caution to patients with lymphatic leukemia since they are especially susceptible to amoxicillin induced skin rashes.

Use in lactation:

- Amoxicillin is excreted in the milk; there is no data on the excretion of clavulanic acid in human milk. Therefore, caution should be exercised when CLAMENTIN 1000 mg is administered to a nursing woman that is breastfeeding her baby.
- The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP) (see section 4.8). This reaction requires CLAMENTIN 1000 mg discontinuation and contraindicates any subsequent administration of amoxicillin.

Interference with laboratory tests:

- During treatment with CLAMENTIN 1000 mg, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non-enzymatic methods (see section 4.5).

Interference with serological testing:

- CLAMENTIN 1000 mg may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.

1.3.1.1 Professional Information for medicines for human use

4.5 Interaction with other medicines and other forms of Interaction

Probenecid:

- Probenecid decreases the renal tubular secretion of amoxicillin but does not affect clavulanic acid excretion.
- Concurrent use with CLAMENTIN 1000 mg may result in increased and prolonged blood levels of amoxicillin, but not of clavulanic acid.

Oral contraceptives:

- CLAMENTIN 1000 mg may reduce the efficacy of oral contraceptives and patients should be warned accordingly.

Allopurinol:

- The concomitant administration of allopurinol and ampicillin substantially increases the incidence of skin rashes in patients receiving both medicines as compared to patients receiving ampicillin alone (*see section 4.4*).
- It is not known whether this potentiation of ampicillin rashes is due to allopurinol or the hyperuricaemia present in these patients.
- There is no data on CLAMENTIN 1000 mg ENTIN and allopurinol administered concurrently.

Tetracyclines:

- Tetracyclines and other bacteriostatic drugs medicines may interfere with the bactericidal effects of CLAMENTIN 1000 mg.

Interaction with laboratory tests:

- It is recommended that when testing for the presence of glucose in urine during CLAMENTIN 1000 mg treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of CLAMENTIN 1000 mg, false positive readings are common with chemical methods (*see section 4.4 'Interference with laboratory tests'*).

1.3.1.1 Professional Information for medicines for human use

Oral anticoagulants:

- The prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of CLAMENTIN 1000 mg. Moreover, adjustments in the dose of oral anticoagulants may be necessary (*see sections 4.4 and 4.8*).

Methotrexate:

- CLAMENTIN 1000 mg may reduce the excretion of methotrexate causing a potential increase in toxicity.

Mycophenolate mofetil:

- In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) has been reported following commencement of oral CLAMENTIN 1000 mg. Close monitoring should be performed during the combination and shortly after antibiotic treatment.

4.6 Fertility, pregnancy and lactation

Woman of childbearing potential

CLAMENTIN 1000 mg may reduce the efficacy of oral contraceptives and patients should be warned accordingly (*see section 4.5*).

Pregnancy

The safety of CLAMENTIN 1000 mg in pregnancy has not been established.

Breastfeeding

Amoxicillin as contained in CLAMENTIN 1000 mg is distributed into breast milk.

Although significant problems in humans have not been documented, the use of CLAMENTIN 1000 mg by breastfeeding mothers may lead to sensitisation, diarrhoea, *Candidiasis* and skin rash in the infant.

1.3.1.1 Professional Information for medicines for human use

4.7 Effects on ability to drive and use machines

CLAMENTIN 1000 mg may cause allergic reactions, dizziness or convulsions which may influence mental and/or physical abilities to perform or execute tasks or activities requiring mental alertness, judgment and/or sound coordination and vision (*see section 4.4 & 4.8*).

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse effects are diarrhoea, nausea, vomiting, indigestion, abdominal pain, skin rashes, urticaria and erythema multiforme, vaginitis, abnormal taste, headache, dizziness, tiredness and hot flushes.

The incidence and severity of adverse effects, particularly nausea and diarrhoea, increased with the higher recommended dose and can be minimised by administering CLAMENTIN 1000 mg at the start of a meal. In addition, as these symptoms are especially related to the potassium clavulanate component, where these gastro-intestinal symptoms occur and a higher concentration of amoxicillin is required, consideration should be given to administering the additional amoxicillin separately.

The following adverse reactions have been reported and may occur with CLAMENTIN 1000 mg:

Tabulated list of adverse reactions

Body System	Undesirable effect		
	Frequent	Less frequent	Frequency not known
Infections and Infestations:	<i>Mucocutaneous candidiasis</i>		Overgrowth of non-susceptible organisms

1.3.1.1 Professional Information for medicines for human use

Blood and the lymphatic system disorders ⁵ :	Thrombocytopenic purpura, Eosinophilia	Reversible leucopenia (including neutropenia) and thrombocytopenia	Haemolytic anaemia, Prolongation of bleeding time and prothrombin time (see section 4.4), Reversible agranulocytosis
Immune system disorders (see section 4.3 & 4.4):			Fatal hypersensitivity (anaphylactic) reactions and angioneurotic oedema, Serum sickness-like syndrome, Hypersensitivity vasculitis, Stevens-Johnson syndrome, Bullous exfoliative dermatitis and toxic epidermal necrolysis (see section 4.4)
Nervous system disorders:		Dizziness, Headache	Reversible hyperactivity, Convulsions ⁶ (see section 4.4), Aseptic meningitis
Cardiac disorders:			Kounis syndrome (see section 4.4)
Gastrointestinal disorders ¹ :	Nausea, Vomiting, Diarrhoea, Gastritis, Stomatitis, Glossitis, Enterocolitis	Indigestion	Antibiotic-associated colitis (including pseudomembranous colitis, haemorrhagic colitis (see section 4.4), Black hairy tongue, Drug-induced enterocolitis syndrome (DIES) (see section 4.4), Pancreatitis acute

1.3.1.1 Professional Information for medicines for human use

Hepato-biliary disorders ² :		Increased aspartate transaminase (AST), alanine transaminase (ALT) ³	Hepatitis and cholestatic jaundice ⁹
Skin and subcutaneous tissue disorders ⁴ :		Skin rashes, Pruritus and urticaria, Erythema multiforme	Acute generalised exanthemous pustulosis (AGEP) (see section 4.4), Drug reaction with eosinophilia and systemic symptoms (DRESS), Linear IgA disease
Renal and urinary disorders:			Interstitial nephritis, Crystalluria (including acute renal injury) (see section 4.9) ⁸
General disorders and administrative site conditions:			Superficial tooth discolouration ⁷

¹ Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking CLAMENTIN 1000 mg with a meal.

² The events may be severe, and occur predominantly in adult or elderly patients. Signs and symptoms usually occur during or shortly after treatment, but in some cases may not become apparent until several weeks after treatment has ceased. **The hepatic effects are usually reversible. However, in extremely rare circumstances, death has been reported. These have almost always been cases associated with serious underlying disease or concomitant medication.**

³ A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics.

⁴ Whenever such reactions occur, CLAMENTIN 1000 mg should be discontinued. Serious and occasional fatal hypersensitivity (anaphylactic) reactions and angioneurotic oedema can occur with oral penicillin (see section 4.4).

⁵ These reactions are usually reversible on discontinuation of therapy and are believed to be hypersensitivity phenomena. A slight thrombocytosis was noted in less than 1 % of the

1.3.1.1 Professional Information for medicines for human use

patients treated with CLAMENTIN 1000 mg. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly.

⁶ Convulsions may occur with impaired renal function or in those receiving high doses.

⁷ Superficial tooth discolouration has been reported especially with the suspension and chewable tablet formulations. It can usually be removed by brushing.

⁸ See section 4.9.

⁹ These events have been noted with other penicillins and cephalosporins (*see section 4.4*).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare providers are asked to report any suspected adverse reactions to SAHPRA via the “**6.04 Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications:

<https://www.sahpra.org.za/Publications/Index/8>.

4.9 Overdose

In overdose, side effects can be precipitated and/or be of increased severity (*see section 4.8*).

Symptoms:

- Overdosage with amoxicillin as contained in CLAMENTIN 1000 mg is usually asymptomatic.
- Gastro-intestinal effects such as nausea, vomiting and diarrhoea may be evident and symptoms of water and electrolyte imbalance should be treated symptomatically.
- Adequate fluid intake and urinary output must be maintained to minimise the possibility of crystalluria.

Treatment:

- Amoxicillin as contained in CLAMENTIN 1000 mg may be removed from the circulation by haemodialysis. The molecular weight, degree of protein binding and

1.3.1.1 Professional Information for medicines for human use

pharmacokinetic profile of clavulanic acid together with information from a single patient with renal insufficiency all suggest that this compound may also be removed by haemodialysis.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

PHARMACOLOGICAL CLASSIFICATION:

A 20.1.2 Penicillins

Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors; ATC code: J01CR02.

Mechanism of action:

CLAMENTIN 1000 mg is a combination of amoxicillin and clavulanic acid.

Amoxicillin is a semisynthetic beta-lactamase-susceptible penicillin, which has in vitro bactericidal activity against broad spectrum of non-beta-lactamase-producing Gram positive and Gram-negative organisms. The spectrum of activity does not include those organisms that produce beta-lactamases, namely resistant staphylococci, and all strains of *Pseudomonas*, *Klebsiella* and *Enterobacter*.

Clavulanic acid has been shown in vitro to be an irreversible inhibitor of beta-lactamases produced by: *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Proteus vulgaris*, *Haemophilus influenzae*, *Neisseria gonorrhoea* and *Bacteroides fragilis*. Clavulanic acid does not inactivate the chromosomally mediated (Sykes Type 1 *Cephalosporinase*) beta-lactamases produced by *Acinetobacter species*, *Citrobacter species*, *Enterobacter*, *Indole positive Proteus*, *Providencia species* and *Serratia marcescens*. In vitro the formulation showed synergism against amoxicillin-resistant organisms, with no evidence of antagonism and the activity was not reduced in the presence of serum. (In vitro

1.3.1.1 Professional Information for medicines for human use

activity does not necessarily imply in vivo efficacy). The clavulanic acid component has very little bactericidal action.

5.2 Pharmacokinetic properties

Amoxicillin:

Absorption:

Amoxicillin is stable in the presence of acidic gastric secretions. Peak blood levels are achieved 1 - 2 hours after administration. There is a linear dose response in peak serum levels.

The pharmacokinetics of amoxicillin and clavulanic acid are closely allied and neither is adversely affected by the presence of food in the stomach.

Distribution:

Approximately 18 % of the total plasma amoxicillin content is protein bound. Amoxicillin diffuses readily into most body tissues with the exception of the brain and spinal fluid. Inflammation generally increases the permeability of the meninges to penicillins and this may apply to amoxicillin.

Excretion:

The elimination half-life of amoxicillin is approximately 1 hour. Co-administration of probenecid has little effect on the excretion of the clavulanic acid component of the formulation. Small amounts of amoxicillin are also excreted in the faeces and bile.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core:

1.3.1.1 Professional Information for medicines for human use

Talc, povidone, microcrystalline cellulose, magnesium stearate, croscarmellose cellulose, purified water, silicon dioxide colloidal

Tablet film-coat consisting of:

Triethyl citrate, ethyl cellulose aqueous dispersion, hypromellose, talc, titanium dioxide, purified water

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

36 months.

6.4 Special precautions for storage

Store at or below 25°C.

Store in a cool place.

Protect from light and moisture.

6.5 Nature and contents of container

Tablets are packed in aluminium foil, soft, 30 µm, with PE coating, printed for sealing package.

10, 15, 16, 21, 30, 50, 90, 100 or 500 tablets will be packed in a cardboard box.

6.6 Special precautions for disposal of a used medicine or waste materials derived from such medicine and other handling of the product

Any unused medicine or waste material should be disposed of in accordance with local requirements.

1.3.1.1 Professional Information for medicines for human use

7 HOLDER OF THE CERTIFICATE OF REGISTRATION

Viatrix Healthcare (Pty) Ltd

4 Brewery Street

Isando, 1609

Gauteng

Republic of South Africa

8 REGISTRATION NUMBER(S)

A40/20.1.2/0088

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

21 February 2006

10 DATE OF REVISION OF TEXT

20 February 2024